May 28, 2021 -- August Bioservices has raised about $24 million in funding to expand its biomanufacturing capabilities in the U.S.
The funds will be used to advance technology needed to support the production of sterile injectable medications. This includes current good manufacturing practice (cGMP) nonsterile and bulk manufacturing, aseptic fill and finish, labeling, and related services. The company also provides drug formulation, process design and scale-up, analytical and stability testing, and research services that feature target validation, characterization and assay development, protein engineering, and cell line development.
The series A extension was led by Polaris Partners.
Copyright © 2021 scienceboard.net